Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Monte Rosa Therapeutics Inc (GLUE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: GLUE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.75
1 Year Target Price $15.75
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.95% | Avg. Invested days 21 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 282.95M USD | Price to earnings Ratio 38.33 | 1Y Target Price 15.75 |
Price to earnings Ratio 38.33 | 1Y Target Price 15.75 | ||
Volume (30-day avg) 9 | Beta 1.4 | 52 Weeks Range 3.50 - 12.40 | Updated Date 06/30/2025 |
52 Weeks Range 3.50 - 12.40 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.86% | Operating Margin (TTM) 51.85% |
Management Effectiveness
Return on Assets (TTM) -0.4% | Return on Equity (TTM) 2.88% |
Valuation
Trailing PE 38.33 | Forward PE 10.27 | Enterprise Value -1879922 | Price to Sales(TTM) 1.77 |
Enterprise Value -1879922 | Price to Sales(TTM) 1.77 | ||
Enterprise Value to Revenue 28.78 | Enterprise Value to EBITDA 3.9 | Shares Outstanding 61509800 | Shares Floating 29133512 |
Shares Outstanding 61509800 | Shares Floating 29133512 | ||
Percent Insiders 0.73 | Percent Institutions 100.81 |
Analyst Ratings
Rating 3 | Target Price 15.75 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Monte Rosa Therapeutics Inc
Company Overview
History and Background
Monte Rosa Therapeutics was founded in 2018. It is a biotechnology company focused on developing novel small molecule protein degrader therapeutics.
Core Business Areas
- Molecular Glue Degraders: Focuses on discovering and developing molecular glue degraders that selectively eliminate disease-causing proteins.
- Undruggable Target Focus: Aims to develop therapies against proteins previously considered 'undruggable'.
Leadership and Structure
The leadership team includes Markus Warmuth, CEO, and other executives in R&D, finance, and operations. The organizational structure involves research, preclinical development, and clinical development teams.
Top Products and Market Share
Key Offerings
- MRT-2359 (GSPT1 degrader): An oral GSPT1 degrader in Phase 1/2 clinical trials for MYC-driven cancers. No significant revenue generated yet; competes with other emerging degrader technologies. Competitors are Arvinas, Kymera Therapeutics, and others in the targeted protein degradation space.
- Molecular Glue Discovery Platform: Their proprietary platform for identifying and developing novel molecular glue degraders. Its success will impact the pipeline's value. Competitors include other companies with similar platforms and companies focusing on E3 ligase modulators.
Market Dynamics
Industry Overview
The targeted protein degradation (TPD) field is rapidly evolving, with significant investment and increasing clinical validation. The market is competitive and driven by innovation.
Positioning
Monte Rosa is positioned as a leader in the molecular glue degrader space, focusing on highly selective and potent degraders. Competitive advantages include their platform and early clinical data.
Total Addressable Market (TAM)
The TAM for targeted protein degradation is estimated to be in the tens of billions of dollars, addressing a wide range of diseases. Monte Rosa is focused on specific cancer subtypes and other indications. Their share of TAM depends on success of clinical trials.
Upturn SWOT Analysis
Strengths
- Proprietary molecular glue degrader platform
- Strong scientific team
- Early clinical data demonstrating proof-of-concept
- Focus on undruggable targets
Weaknesses
- Early-stage clinical development (high risk)
- Dependence on platform success
- Cash burn rate
- Vulnerability to competitors with similar technologies
Opportunities
- Expansion of pipeline with new degrader programs
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Advancements in understanding of E3 ligase biology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other TPD companies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- ARVN
- KYMR
Competitive Landscape
Monte Rosa faces strong competition in the TPD space. Their success depends on demonstrating superior efficacy, selectivity, and safety of their degraders.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily tied to advancement of their pipeline and preclinical programs.
Future Projections: Analyst projections vary; dependent on clinical trial outcomes and partnerships.
Recent Initiatives: Advancing MRT-2359 in clinical trials, expanding degrader platform, and seeking strategic collaborations.
Summary
Monte Rosa Therapeutics is a biotechnology company focused on molecular glue degraders. They are in early-stage clinical development, which presents risks and opportunities. Their platform technology gives them a competitive advantage, but clinical success is essential. The company needs to watch out for competitive pressures and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and based on available public information. Financial data may not be fully up to date.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monte Rosa Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-06-24 | President, CEO & Director Dr. Markus Warmuth M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 142 | Website https://www.monterosatx.com |
Full time employees 142 | Website https://www.monterosatx.com | ||
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.